Are you an attorney or plaintiff with slow-paying pharmaceutical settlements? If so, RD Legal Funding can convert your settled cases into immediate cash via our proprietary Fee Acceleration post-settlement funding program. Simply fill out the quick form to the right to begin the application process. You can also reach us at 1-800-565-5177 to speak with a Fee Acceleration expert.
Pharmaceutical litigation pursues companies that are guilty of pharmaceutical malpractice. The majority of these suits involve:
In this country, the U.S. Food and Drug Administration (FDA) is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, the food supply, cosmetics, and products that emit radiation. The agency is also responsible for advancing public health by helping to speed up innovations that make medicines more effective, safer, and more affordable. Unfortunately, the FDA is not always up to the task.
The pharmaceutical companies which paid the five largest settlements all violated the False Claims Act, a federal law that imposes liability on companies who defraud governmental programs. The Federal Food, Drug, and Cosmetic Act (FDCA), which allows the FDA to oversee the safety of food, drugs, and cosmetics, is also involved in many of these cases.
GlaxoSmithKline paid $3 billion in 2012 for failing to disclose safety data and engaging in off-label promotion with its drugs Avandia (an antidiabetic drug), and antidepressants Wellbutrin and Paxil.
Pfizer paid $2.3 billion in 2009 for off-label promotion and paying kickbacks for its drugs Bextra (a non-steroidal anti-inflammatory), Geodon (an antipsychotic), Zyvox (for the treatment of antibiotic-resistant infections) and Lyrica (an anticonvulsant drug).
Abbott Laboratories paid $1.5 billion in 2012 for off-label promotion of Depakote (an anticonvulsant and mood-stabilizing drug).
Eli Lilly paid $1.4 billion in 2009 for off-label promotion of Zyprexa (an antipsychotic).
Johnson & Johnson and subsidiary Janssen violated the State of Arkansas’ Medicaid fraud laws 238,000 times by illegally marketing the antipsychotic drug Risperdal, resulting in over $1.1 billion in fines. Additional fines of at least an additional $1 billion are pending with the U.S. Department of Justice over mis-marketing of Risperdal and the antipsychotic Invega and cardiovascular drug Natrecor.
Among current major pharmaceutical litigations underway, Takeda Pharmaceutical Co. may have averted a $6.5 million jury verdict over its Actos diabetes drug. The cancer-treatment drug Avastin has been linked to 52 cases of flesh-eating disease. Eli Lilly and Co. has settled a wrongful death case involving the antidepressant Cymbalta but other cases are pending. GE Healthcare Inc. lost a $5 million verdict over Ominscan dye which causes hardening of the skin and makes it difficult to move limbs. A federal judge in Alabama has ordered mediation for Pfizer’s remaining 2,700 smoking-cessation drug Chantix cases. Merck is mired in litigation alleging it hid the bone-weakening risks of its osteoporosis drug, Foxamax.
RD Legal Funding is positioned to provide immediate post-settlement attorney fee funding and plaintiff financing for those with slow-paying pharmaceutical related settlements. Please fill out the brief online application located at the upper right corner of this page to start accelerating your legal fees today. Or you can call RD Legal toll-free at 1-800-565-5177 to speak with one of our legal funding experts.